Vertex Pharmaceuticals

Global biotechnology company.

Based in MA

🤖

AI Overview

With $2.0M in lobbying spend across 28 quarterly filings, Vertex Pharmaceuticals is a significant lobbying presence.

$2.0M
Total Lobbying Spend
28
Quarterly Filings
1
Lobbying Firms Used
7
Individual Lobbyists

Spending by Year

YearLobbying Spend
2018$240K
2019$120K
2020$280K
2021$240K
2022$240K
2023$320K
2024$320K
2025$280K

Lobbying Firms

TIBER CREEK GROUP

What They Lobby For

  • Issues surrounding treatment of rare diseases. Issues related to price and transparency.
  • Issues related to price and transparency. Issues related to Part D drug benefit.
  • HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - Issues related to drug pricing.
  • HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - Issues related to drug pricing. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
  • Issues related to drug pricing. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
  • Issues related to drug pricing. H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
  • Issues related to drug pricing; Issues related to Sickle Cell disease.
  • Issues related to drug pricing; Issues related to face to face meetings improve oversight of agency commitments.
  • Issues related to drug pricing; Issues related to face-to-face meetings improve oversight of agency commitments: issues relating to cancer research.
  • Issues related to drug pricing; Issues related to H.R.7142/S.3832 - Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.